Helix B surface peptide attenuates diabetic cardiomyopathy via AMPK-dependent autophagy

Biochemical and Biophysical Research Communications

Volumn 482, Issue 4, 2017, Pages 665-671

  Lin, Chen ^a   Zhang, Mingming ^a   Zhang, Yingmei ^b   Yang, Kejian ^a   Hu, Jianqiang ^a   Si, Rui ^a   Zhang, Guoyong ^a   Gao, Beilei ^a   Li, Xiang ^a   Xu, Chennian ^a   Li, Congye ^a   Hao, Qimeng ^c   Guo, Wenyi ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Autophagy; Diabetic cardiomyopathy; Helix B surface peptide

Indexed keywords

3 METHYLADENINE; GLUCOSE; HELIX B SURFACE PEPTIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MAMMALIAN TARGET OF RAPAMYCIN; PEPTIDE; RAPAMYCIN; SEQUESTOSOME 1; SERINE; SODIUM CHLORIDE; THREONINE; UNCLASSIFIED DRUG; ERYTHROPOIETIN; GLUTAMINYL-GLUTAMYL-GLUTAMINYL-LEUCYL-GLUTAMYL-ARGINYL-ALANYL-LEUCYL-ASPARAGYL-SERYL-SERINE; INTERLEUKIN 6; INTERLEUKIN-6, MOUSE; PEPTIDE FRAGMENT; STREPTOZOCIN; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; AUTOPHAGOSOME; AUTOPHAGY; CARDIAC MYOBLAST; CELL ULTRASTRUCTURE; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; ENZYME PHOSPHORYLATION; HEART FUNCTION; HEART MITOCHONDRION; HEART MUSCLE FIBROSIS; IN VITRO STUDY; MALE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; WESTERN BLOTTING; ANIMAL; C57BL MOUSE; CARDIAC MUSCLE; CHEMISTRY; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC CARDIOMYOPATHIES; DRUG EFFECTS; ECHOCARDIOGRAPHY; HEMATOCRIT; MEMBRANE POTENTIAL; METABOLISM; MITOCHONDRION; PATHOLOGY; RAT; TUMOR CELL LINE;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; APOPTOSIS; AUTOPHAGY; CELL LINE, TUMOR; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC CARDIOMYOPATHIES; ECHOCARDIOGRAPHY; ERYTHROPOIETIN; HEMATOCRIT; INTERLEUKIN-6; MALE; MEMBRANE POTENTIALS; MICE; MICE, INBRED C57BL; MITOCHONDRIA; MYOCARDIUM; PEPTIDE FRAGMENTS; RATS; STREPTOZOCIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 85007232615     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2016.11.091     Document Type: Article

References (39)

1. [1] Kannel, W.B., McGee, D.L., Diabetes and cardiovascular disease. The Framingham study. Jama 241 (1979), 2035–2038.
2. [2] Mano, Y., Anzai, T., Kaneko, H., et al. Overexpression of human C-reactive protein exacerbates left ventricular remodeling in diabetic cardiomyopathy. Circ. J. 75 (2011), 1717–1727.
3. [3] Wang, J., Wang, H., Hao, P., et al. Inhibition of aldehyde dehydrogenase 2 by oxidative stress is associated with cardiac dysfunction in diabetic rats. Mol. Med. 17 (2011), 172–179.
4. [4] Duncan, J.G., Mitochondrial dysfunction in diabetic cardiomyopathy. Biochim. Biophys. Acta 1813 (2011), 1351–1359.
5. [5] Asbun, J., Villarreal, F.J., The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J. Am. Coll. Cardiol. 47 (2006), 693–700.
6. [6] Palazzuoli, A., Ruocco, G., Pellegrini, M., et al. The role of erythropoietin stimulating agents in anemic patients with heart failure: solved and unresolved questions. Ther. Clin. Risk. Manag. 10 (2014), 641–650.
7. [7] Li, F., Chong, Z.Z., Maiese, K., Erythropoietin on a tightrope: balancing neuronal and vascular protection between intrinsic and extrinsic pathways. Neurosignals 13 (2004), 265–289.
8. [8] Gassmann, M., Heinicke, K., Soliz, J., et al. Non-erythroid functions of erythropoietin. Adv. Exp. Med. Biol. 543 (2003), 323–330.
9. [9] Ehrenreich, H., Weissenborn, K., Prange, H., et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. Stroke 40 (2009), e647–656.
10. [10] Brines, M., Patel, N.S., Villa, P., et al. Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 10925–10930.
11. [11] Ahmet, I., Tae, H.J., Brines, M., et al. Chronic administration of small nonerythropoietic peptide sequence of erythropoietin effectively ameliorates the progression of postmyocardial infarction-dilated cardiomyopathy. J. Pharmacol. Exp. Ther. 345 (2013), 446–456.
12. [12] McVicar, C.M., Hamilton, R., Colhoun, L.M., et al. Intervention with an erythropoietin-derived peptide protects against neuroglial and vascular degeneration during diabetic retinopathy. Diabetes 60 (2011), 2995–3005.
13. [13] Taneike, M., Yamaguchi, O., Nakai, A., et al. Inhibition of autophagy in the heart induces age-related cardiomyopathy. Autophagy 6 (2010), 600–606.
14. [14] Kim, J., Kundu, M., Viollet, B., et al. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat. Cell Biol. 13 (2011), 132–141.
15. [15] Langer, S., Kreutz, R., Eisenreich, A., Metformin modulates apoptosis and cell signaling of human podocytes under high glucose conditions. J. Nephrol. 29 (2016), 765–773.
16. [16] Xie, Z., Lau, K., Eby, B., et al. Improvement of cardiac functions by chronic metformin treatment is associated with enhanced cardiac autophagy in diabetic OVE26 mice. Diabetes 60 (2011), 1770–1778.
17. [17] Guo, Y., Yu, W., Sun, D., et al. A novel protective mechanism for mitochondrial aldehyde dehydrogenase (ALDH2) in type i diabetes-induced cardiac dysfunction: role of AMPK-regulated autophagy. Biochim. Biophys. Acta 1852 (2015), 319–331.
18. [18] Zhao, Y., Zhang, L., Qiao, Y., et al. Heme oxygenase-1 prevents cardiac dysfunction in streptozotocin-diabetic mice by reducing inflammation, oxidative stress, apoptosis and enhancing autophagy. Plos One, 8, 2013, e75927.
19. [19] Zhou, G., Li, X., Hein, D.W., et al. Metallothionein suppresses angiotensin II-induced nicotinamide adenine dinucleotide phosphate oxidase activation, nitrosative stress, apoptosis, and pathological remodeling in the diabetic heart. J. Am. Coll. Cardiol. 52 (2008), 655–666.
20. [20] Deka, S., Vanover, J., Sun, J., et al. An early event in the herpes simplex virus type-2 replication cycle is sufficient to induce Chlamydia trachomatis persistence. Cell Microbiol. 9 (2007), 725–737.
21. [21] Liu, Y., Luo, B., Shi, R., et al. Nonerythropoietic erythropoietin-derived peptide suppresses adipogenesis, inflammation, obesity and insulin resistance. Sci. Rep., 5, 2015, 15134.
22. [22] Ma, H., Guo, R., Yu, L., et al. Aldehyde dehydrogenase 2 (ALDH2) rescues myocardial ischaemia/reperfusion injury: role of autophagy paradox and toxic aldehyde. Eur. Heart. J. 32 (2011), 1025–1038.
23. [23] Seglen, P.O., Gordon, P.B., 3-Methyladenine: specific inhibitor of autophagic/lysosomal protein degradation in isolated rat hepatocytes. Proc. Natl. Acad. Sci. U. S. A. 79 (1982), 1889–1892.
24. [24] Guo, R., Scott, G.I., Ren, J., Involvement of AMPK in alcohol dehydrogenase accentuated myocardial dysfunction following acute ethanol challenge in mice. Plos One, 5, 2010, e11268.
25. [25] Jiang, T., Yu, J.T., Zhu, X.C., et al. Ischemic preconditioning provides neuroprotection by induction of AMP-activated protein kinase-dependent autophagy in a rat model of ischemic stroke. Mol. Neurobiol. 51 (2015), 220–229.
26. [26] Zhang, M., Sun, D., Li, S., et al. Lin28a protects against cardiac ischaemia/reperfusion injury in diabetic mice through the insulin-PI3K-mTOR pathway. J. Cell Mol. Med. 19 (2015), 1174–1182.
27. [27] Collino, M., Thiemermann, C., Cerami, A., et al. Flipping the molecular switch for innate protection and repair of tissues: long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin. Pharmacol. Ther. 151 (2015), 32–40.
28. [28] Brines, M., Grasso, G., Fiordaliso, F., et al. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 14907–14912.
29. [29] Chen, L.N., Sun, Q., Liu, S.Q., et al. Erythropoietin improves glucose metabolism and pancreatic beta-cell damage in experimental diabetic rats. Mol. Med. Rep. 12 (2015), 5391–5398.
30. [30] Silverberg, D.S., Wexler, D., Blum, M., et al. The effect of correction of anaemia in diabetics and non-diabetics with severe resistant congestive heart failure and chronic renal failure by subcutaneous erythropoietin and intravenous iron. Nephrol. Dial. Transplant. 18 (2003), 141–146.
31. [31] Maiese, K., Erythropoietin and diabetes mellitus. World J. Diabetes 6 (2015), 1259–1273.
32. [32] Yang, C., Xu, Z., Zhao, Z., et al. A novel proteolysis-resistant cyclic helix B peptide ameliorates kidney ischemia reperfusion injury. Biochim. Biophys. Acta 1842 (2014), 2306–2317.
33. [33] Brines, M., Dunne, A.N., van Velzen, M., et al. ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes. Mol. Med. 20 (2014), 658–666.
34. [34] Lorenzo, O., Picatoste, B., Ares-Carrasco, S., et al. Potential role of nuclear factor kappaB in diabetic cardiomyopathy. Mediat. Inflamm., 2011, 2011, 652097.
35. [35] Lewis, P., Stefanovic, N., Pete, J., et al. Lack of the antioxidant enzyme glutathione peroxidase-1 accelerates atherosclerosis in diabetic apolipoprotein E-deficient mice. Circulation 115 (2007), 2178–2187.
36. [36] Sun, S., Zhang, M., Lin, J., et al. Lin28a protects against diabetic cardiomyopathy via the PKA/ROCK2 pathway. Biochem. Biophys. Res. Commun. 469 (2016), 29–36.
37. [37] Shimizu, M., Umeda, K., Sugihara, N., et al. Collagen remodelling in myocardia of patients with diabetes. J. Clin. Pathol. 46 (1993), 32–36.
38. [38] Zile, M.R., Brutsaert, D.L., New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation 105 (2002), 1503–1508.
39. [39] Martinet, W., Knaapen, M.W., Kockx, M.M., et al. Autophagy in cardiovascular disease. Trends Mol. Med. 13 (2007), 482–491.